

Cyanocobalamin Degradation

In the May 1976 issue of the Journal, Yazdany and Badii¹ reported on the degradation of cyanocobalamin when autoclaved in the presence of 0.1% methylparaben sodium. This observation is not surprising since cyanocobalamin is known to be inactivated in alkaline solutions² and methylparaben sodium (a sodium phenolate) gives an alkaline pH in solution. Thus, we are dealing here simply with a base-catalyzed degradation. The authors of the paper seem uncognizant of this and suggest instead some undefined direct interaction between the paraben moiety and cyanocobalamin.

The relatively isolated situation of the authors may explain their unawareness of the nature of the reported reaction. It is surprising, however, that the Journal's reviewer failed to call it to their attention.

Stanley Scheindlin
Lemmon Pharmcal Company
Sellersville, PA 18960

Received June 1, 1976.

¹ S. Yazdany and F. Badii, *J. Pharm. Sci.*, **65**, 745(1976).

² A. Osol, "United States Dispensatory," 27th ed., Lippincott, Philadelphia, Pa., 1973, p. 359.

Equations for Bolus Intravenous Injection in Linear Pharmacokinetics

S. Niazi¹ recently stated that in a linear pharmacokinetic model where instantaneous input is assumed (*i.e.*, bolus intravenous injection), the assumption embodied in Eq. 1 is made:

$$\frac{1 - e^{-b_i t}}{b_i \theta} = 1 \quad (\text{Eq. 1})$$

He suggested that the coefficients of the bolus intravenous equation should be corrected by multiplying by the reciprocal of the left-hand side of Eq. 1. I would like to caution readers *not* to make such "corrections," since Eq. 1 is incorrect.

The equations for bolus intravenous injection, during a constant rate intravenous infusion, and after constant rate infusion are shown below. They are derived for different initial conditions but are consistent, and the coefficients may be interconverted by means of Eqs. 5 and 6.

For bolus intravenous injection:

$$C_p = \sum_{i=1}^n C_i e^{-b_i t} \quad (\text{Eq. 2})$$

During an infusion:

$$C_p = \sum_{i=1}^n X_i (1 - e^{-b_i t}) = \sum_{i=1}^n \frac{C_i}{\theta_i \theta} (1 - e^{-b_i t}) \quad (\text{Eq. 3})$$

After infusion:

$$C_p = \sum_{i=1}^n Y_i e^{-b_i t} = \sum_{i=1}^n C_i \left(\frac{e^{+b_i \theta} - 1}{b_i \theta} \right) e^{-b_i t} \quad (\text{Eq. 4})$$

From Eq. 3:

$$C_i = X_i b_i \theta \quad (\text{Eq. 5})$$

From Eq. 4:

$$C_i = \frac{b_i \theta Y_i}{e^{+b_i \theta} - 1} \quad (\text{Eq. 6})$$

In Eqs. 1-6, θ is the infusion time, t is time from the start of administration, and the b_i 's are eigenvalues. For the two-compartment open model, $n = 2$; for the three-compartment open model, $n = 3$.

John G. Wagner
College of Pharmacy and Upjohn Center
for Clinical Pharmacology
University of Michigan
Ann Arbor, MI 48109

Received May 28, 1976.

¹ S. Niazi, *J. Pharm. Sci.*, **65**, 750(1976).

Drug Delivery Systems versus Dosage Forms

The phrase "drug delivery system" is becoming increasingly prominent in professional communications. It would be well to consider the distinction between this phrase and the classic term "dosage form."

As currently used, a drug delivery system is really a dosage form delivery system. It delivers the physical-chemical system, *i.e.*, the solution or suspension, *etc.*, that contains the drug (*e.g.*, a drug in solution contained within a polymeric matrix). Thus, in the case of Ocuser, the polymeric plastic material contains the solution which is the dosage form and which, in turn, contains the dissolved drug, pilocarpine.

By way of illustrating possible confusion, a capsule that is recognized as a dosage form is really a dosage form delivery system. The gelatin capsule itself can deliver any of a variety of physical-chemical systems (dosage forms) such as suspensions, solutions, or powders. A further illustration exists with intravenous injectables. Here the syringe is the dosage form delivery system; the solution, suspension, *etc.*, are the dosage forms containing the drug.

We suggest that the term "drug delivery system" be used to refer to the dosage form. The pharmaceutical community would do well to consider the confusions that are developing through ill-defined terminology.

Bernard Ecanow
Bernard H. Gold
College of Pharmacy
University of Illinois at the Medical
Center
Chicago, IL 60680

Received June 7, 1976.